Literature DB >> 28111228

Targeted Therapies for Ovarian Cancer.

Tami Grunewald1, Jonathan A Ledermann2.   

Abstract

Epithelial ovarian cancer has the highest mortality rate of all gynaecological malignancies. Most women present with advanced disease and develop a recurrence after radical surgery and chemotherapy. Improving the results of first- or subsequent-line chemotherapy has been slow, and novel approaches to systemic treatment are needed. Ovarian cancer is a heterogeneous disease with complex molecular and genetic changes. Understanding these better will provide information on the mechanisms of resistance and opportunities to target therapy more rationally, exploiting specific changes in the tumour. Here we reviewed targeted approaches to therapy, focussing on targeting angiogenesis and inhibition of DNA repair, 2 areas that show promising activity. Additionally, we reviewed studies that are underway, targeting the cell cycle, signalling pathways and immunotherapeutic strategies. Many of these innovative approaches already demonstrate promising activity in ovarian cancer and have the potential to improve the outcome in women with ovarian cancer.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  PARP inhibitor; anti-angiogenesis; immunotherapy; ovarian cancer; targeted therapy

Mesh:

Substances:

Year:  2016        PMID: 28111228     DOI: 10.1016/j.bpobgyn.2016.12.001

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  35 in total

1.  microRNA-26b inhibits growth and cellular invasion of ovarian cancer cells by targeting estrogen receptor α.

Authors:  Guna He; Xiaomei Liu; Lingyu Liu
Journal:  3 Biotech       Date:  2022-07-12       Impact factor: 2.893

2.  Sorafenib inhibits ovarian cancer cell proliferation and mobility and induces radiosensitivity by targeting the tumor cell epithelial-mesenchymal transition.

Authors:  Chuntao Tian; Ying Liu; Lingfei Xue; Dong Zhang; Xiaotong Zhang; Jing Su; Jiaohong Chen; Xiangke Li; Liuxing Wang; Shunchang Jiao
Journal:  Open Life Sci       Date:  2022-06-15       Impact factor: 1.311

3.  Knockdown of ENTPD5 inhibits tumor metastasis and growth via regulating the GRP78/p-eIF-2α/CHOP pathway in serous ovarian cancer.

Authors:  Xueping Chen; Zhiqiang Zha; Yu Wang; Yun Chen; Menglan Pang; Liping Huang; Yao Chen
Journal:  J Ovarian Res       Date:  2022-06-07       Impact factor: 5.506

4.  Targeting Fc Receptor-Mediated Effects and the "Don't Eat Me" Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer.

Authors:  Lei Tian; Bo Xu; Kun-Yu Teng; Mihae Song; Zheng Zhu; Yuqing Chen; Jing Wang; Jianying Zhang; Mingye Feng; Balveen Kaur; Lorna Rodriguez; Michael A Caligiuri; Jianhua Yu
Journal:  Clin Cancer Res       Date:  2021-10-13       Impact factor: 13.801

5.  Lassa-VSV chimeric virus targets and destroys human and mouse ovarian cancer by direct oncolytic action and by initiating an anti-tumor response.

Authors:  A N van den Pol; X Zhang; E Lima; M Pitruzzello; N Albayrak; A Alvero; J N Davis; G Mor
Journal:  Virology       Date:  2020-11-12       Impact factor: 3.616

6.  Mechanism of MicroRNA-375 Promoter Methylation in Promoting Ovarian Cancer Cell Malignancy.

Authors:  Junjun Shu; Ling Xiao; Sanhua Yan; Boqun Fan; Xia Zou; Jun Yang
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

7.  Structure-Based Virtual Screening, Molecular Docking, and Molecular Dynamics Simulation of VEGF inhibitors for the clinical treatment of Ovarian Cancer.

Authors:  Sourav Mukherjee; Mohnad Abdalla; Manasi Yadav; Maddala Madhavi; Anushka Bhrdwaj; Ravina Khandelwal; Leena Prajapati; Aravind Panicker; Aashish Chaudhary; Ashraf Albrakati; Tajamul Hussain; Anuraj Nayarisseri; Sanjeev Kumar Singh
Journal:  J Mol Model       Date:  2022-03-24       Impact factor: 1.810

8.  PSMC2/CCND1 axis promotes development of ovarian cancer through regulating cell growth, apoptosis and migration.

Authors:  Dawei Zhu; Jie Huang; Ning Liu; Wei Li; Limei Yan
Journal:  Cell Death Dis       Date:  2021-07-22       Impact factor: 8.469

9.  NIR Laser Responsive Nanoparticles for Ovarian Cancer Targeted Combination Therapy with Dual-Modal Imaging Guidance.

Authors:  Jiawen Zhao; Liang Zhang; Yingjie Qi; Kui Liao; Zhigang Wang; Ming Wen; Di Zhou
Journal:  Int J Nanomedicine       Date:  2021-06-29

10.  Efficacy of cisplatin combined with topotecan in patients with advanced or recurrent ovarian cancer as second- or higher-line palliative chemotherapy.

Authors:  Myung-Won Lee; Hyewon Ryu; Ik-Chan Song; Hwan-Jung Yun; Deog-Yeon Jo; Young Bok Ko; Hyo-Jin Lee
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.